Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Form 8.3 - Vernalis Plc

8 Oct 2018 15:07

RNS Number : 3245D
Legal & General Investment Mgmnt Ld
08 October 2018
 

FORM 8.3

PUBLIC DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Full name of discloser:

 

Legal And General Investment Management Ltd.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

Legal And General Investment Management Ltd.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

No

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

05 October 2018

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

 

No

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

ORD GBP 0.01

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

7,606,378

 

1.44%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

 

 

7,606,378

 

1.44%

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

N/A

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

ORD GBP 0.01

 

 

Sale

 

2,900,000

 

GBP 0.0614

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

 

NO

 

 

 

Date of disclosure:

 

08 October 2018

Contact name:

 

Nadeem Tariq

Telephone number:

 

02920 35 5444

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETFKFDKQBDDNKK
Date   Source Headline
28th Apr 20177:00 amRNSTotal Voting Rights
26th Apr 20177:00 amRNSServier and Vernalis announce 3 milestones
21st Apr 20177:01 amRNSVernalis receives $2 million milestone payment
21st Apr 20177:00 amRNSFDA Issues Complete Response Letter on CCP-07 NDA
29th Mar 20179:00 amRNSBlock listing Interim Review
6th Mar 20177:00 amRNSNew drug discovery collaboration with Servier
28th Feb 20177:00 amRNSTotal Voting Rights
21st Feb 20177:00 amRNSUnaudited interim results for 6 months to 31/12/16
14th Feb 20177:00 amRNSAchievement of a $3m milestone payment from Corvus
30th Jan 201712:36 pmRNSNotice of Results for Six Months Ended 31/12/2016
21st Dec 20167:00 amRNSFDA accepts CCP-08 NDA for full review
1st Dec 20161:00 pmRNSVernalis Results of Annual General Meeting
1st Dec 20167:00 amRNSAGM Statement
3rd Nov 20164:36 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSTotal Voting Rights
24th Oct 20169:43 amRNSNotice of Annual Report and AGM
13th Oct 201611:58 amRNSHolding(s) in Company
12th Oct 20164:58 pmRNSDirector/PDMR Shareholding
12th Oct 20164:57 pmRNSDirector/PDMR Shareholding
5th Oct 20162:00 pmRNSHolding(s) in Company
5th Oct 20161:02 pmRNSHolding(s) in Company
30th Sep 20163:55 pmRNSDirector/PDMR Shareholding
29th Sep 20163:00 pmRNSBlock listing Interim Review
29th Sep 20167:00 amRNSResults Announcement for 12 months ended 30/06/16
22nd Sep 20161:43 pmRNSHolding(s) in Company
14th Sep 201610:54 amRNSHolding(s) in Company
13th Sep 201610:34 amRNSNotice of Results
6th Sep 20167:00 amRNSFDA accepts CCP-07 NDA for full review
29th Jul 20167:00 amRNSTotal Voting Rights
26th Jul 201612:53 pmRNSHolding(s) in Company
19th Jul 20167:00 amRNSVernalis Achieves Oncology Milestone with Servier
15th Jul 20167:00 amRNSVernalis Notes RedoxTherapies Acquisition by Juno
8th Jul 20167:00 amRNSVernalis Announce CCP-08 Multiple-Dose Results
7th Jul 20161:47 pmRNSYear-end Trading Update and Notice of Results
30th Jun 20167:00 amRNSTotal Voting Rights
24th Jun 20163:52 pmRNSHolding(s) in Company
9th Jun 20162:58 pmRNSDirector Dealing
31st May 20167:00 amRNSTotal Voting Rights
19th May 20164:11 pmRNSMoxatag Supply Update
16th May 20162:44 pmRNSHolding(s) in Company
12th May 201611:10 amRNSResults of General Meeting
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20164:40 pmRNSHolding(s) in Company
26th Apr 20165:17 pmRNSPosting of Circular and Notice of General Meeting
26th Apr 201611:00 amRNSVernalis plc to raise £40 million in Placing
21st Apr 20162:26 pmRNSSandford Sommer appointed as President & COO in US
14th Apr 20167:00 amRNSVernalis Announce CCP-07 Multiple-Dose Results
13th Apr 20167:00 amRNSVernalis Announce CCP-08 Single-Dose Study Results
31st Mar 20169:00 amRNSTotal Voting Rights
29th Mar 20161:55 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.